• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在 COVID-19 住院患者中，瑞德西韦、羟氯喹、洛匹那韦或干扰素β-1a 均与院内死亡率的标准治疗无差异。

In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.

机构信息

Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA (R.Z., E.M.).

出版信息

Ann Intern Med. 2021 Feb;174(2):JC17. doi: 10.7326/ACPJ202102160-017. Epub 2021 Feb 2.

DOI:10.7326/ACPJ202102160-017
PMID:33524282
Abstract

Pan H, Peto R, Henao-Restrepo AM, et al. N Engl J Med. 2020. [Epub ahead of print.] 33264556.

摘要

潘宏教授、皮特教授、Henao-Restrepo 教授等。《新英格兰医学杂志》。2020 年。[在线提前出版]。33264556.

相似文献

1
In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon β-1a differed from standard care for in-hospital mortality.在 COVID-19 住院患者中，瑞德西韦、羟氯喹、洛匹那韦或干扰素β-1a 均与院内死亡率的标准治疗无差异。
Ann Intern Med. 2021 Feb;174(2):JC17. doi: 10.7326/ACPJ202102160-017. Epub 2021 Feb 2.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.瑞德西韦和其他三种药物治疗 COVID-19 住院患者：世卫组织团结随机试验的最终结果和更新的荟萃分析。
Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2.
4
Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.DisCoVeRy试验方案：住院成人COVID-19治疗安全性和有效性的多中心、适应性、随机试验
BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.
5
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.干扰素 β1a 对比干扰素 β1b 和常规治疗方案治疗中重度 COVID-19 成人患者的效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.
6
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.评价瑞德西韦和羟氯喹对 COVID-19 患者病毒清除效果的随机试验。
Ann Intern Med. 2021 Sep;174(9):1261-1269. doi: 10.7326/M21-0653. Epub 2021 Jul 13.
7
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.一项关于洛匹那韦/利托那韦、洛匹那韦/利托那韦联合 IFN-β-1a 和羟氯喹对 COVID-19 住院患者疗效的开放性随机对照试验。
Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26.
8
Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement.瑞德西韦可改善 COVID-19 成年住院患者的康复时间和下呼吸道受累情况。
Ann Intern Med. 2020 Jul 21;173(2):JC4. doi: 10.7326/ACPJ202007210-005.
9
Comparing the outcomes of treatment with INF-β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients.比较 COVID-19 住院患者中使用 INF-β 1-a（干扰素 beta-1a）和 IFN-β 1-b（干扰素 beta-1b）治疗的结果。
Int Immunopharmacol. 2021 Dec;101(Pt B):108241. doi: 10.1016/j.intimp.2021.108241. Epub 2021 Oct 15.
10
Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.瑞德西韦治疗与 COVID-19 住院美国退伍军人的生存和住院时间的关系。
JAMA Netw Open. 2021 Jul 1;4(7):e2114741. doi: 10.1001/jamanetworkopen.2021.14741.

引用本文的文献

1
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.COVID-19 与贫血和血液系统恶性肿瘤患者：风险因素、临床指南和新兴治疗方法。
Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.
2
Global Emergence of SARS-CoV2 Infection and Scientific Interventions to Contain its Spread.全球 SARS-CoV2 感染的出现及科学干预措施以遏制其传播。
Curr Protein Pept Sci. 2024;25(4):307-325. doi: 10.2174/0113892037274719231212044235.
3
M-targeted anti-SARS-CoV-2 inhibitor-based drugs.
基于M靶点的抗SARS-CoV-2抑制剂的药物。
J Chem Res. 2023 Jul 3;47(4):17475198231184799. doi: 10.1177/17475198231184799. eCollection 2023 Jul-Aug.
4
Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19.利用毒液动物源性毒素对抗 COVID-19。
Toxins (Basel). 2023 Feb 14;15(2):159. doi: 10.3390/toxins15020159.
5
Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs.优化 COVID-19 药物临床疗效的药代动力学考虑因素。
Trends Pharmacol Sci. 2022 Dec;43(12):1041-1054. doi: 10.1016/j.tips.2022.09.005. Epub 2022 Sep 26.
6
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体的生物学特性：流行病学影响和临床后果
Vaccines (Basel). 2022 Jun 9;10(6):919. doi: 10.3390/vaccines10060919.
7
[Enoxaparin dose associated with decreased risk of death in COVID-19].[与降低COVID-19死亡风险相关的依诺肝素剂量]
Rev Med Inst Mex Seguro Soc. 2022 Feb 1;60(1):33-39.
8
Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.新型冠状病毒2型抗病毒药物给药的分子见解：安全性与对心血管表型影响之间的平衡
Biomedicines. 2022 Feb 14;10(2):437. doi: 10.3390/biomedicines10020437.
9
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的变异及当前疫苗的前沿研究
Front Med (Lausanne). 2022 Jan 18;8:806641. doi: 10.3389/fmed.2021.806641. eCollection 2021.
10
Antiviral and Immunomodulatory Effects of Root Extract EPs® 7630 in SARS-CoV-2-Infected Human Lung Cells.根提取物EPs® 7630对感染SARS-CoV-2的人肺细胞的抗病毒和免疫调节作用
Front Pharmacol. 2021 Oct 25;12:757666. doi: 10.3389/fphar.2021.757666. eCollection 2021.